Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
DOI
 |
Open Access Gold |
|
as soon as is submitted to ZB.
CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.
Cell Rep. Med. 5:101572 (2024)
Acute myeloid leukemia (AML) is characterized by the accumulation of immature myeloid cells in the bone marrow and the peripheral blood. Nearly half of the AML patients relapse after standard induction therapy, and new forms of therapy are urgently needed. Chimeric antigen receptor (CAR) T therapy has so far not been successful in AML due to lack of efficacy and safety. Indeed, the most attractive antigen targets are stem cell markers such as CD33 or CD123. We demonstrate that CD37, a mature B cell marker, is expressed in AML samples, and its presence correlates with the European LeukemiaNet (ELN) 2017 risk stratification. We repurpose the anti-lymphoma CD37CAR for the treatment of AML and show that CD37CAR T cells specifically kill AML cells, secrete proinflammatory cytokines, and control cancer progression in vivo. Importantly, CD37CAR T cells display no toxicity toward hematopoietic stem cells. Thus, CD37 is a promising and safe CAR T cell AML target.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Acute Myeloid Leukemia ; Aml ; Car T Cell ; Cd37 ; Chimeric Antigen Receptor ; Hematopoietic Stem Cell ; Immunotherapy ; Patient-derived Xenograft; Car T-cell; Antibody-drug Conjugate; Expression; Aml; Efficacy; Siglec-6; Therapy; Protein; Cancer
ISSN (print) / ISBN
2666-3791
e-ISSN
2666-3791
Journal
Cell Reports Medicine
Quellenangaben
Volume: 5,
Issue: 6,
Article Number: 101572
Publisher
Cell Press
Publishing Place
50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of AI for Health (AIH)
Unit for Clinical Pharmacology (KKG-EKLiP)
Unit for Clinical Pharmacology (KKG-EKLiP)
Grants
Fritz Bender Foundation
Research Council of Norway
Norwegian Health Authority South-East
Norwegian Cancer Society
Research Council of Norway (NFR)
University of Bergen PhD fellowship
Marie Sklodowska-Curie Program Training Network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union
Hector Foundation
Deutsche Forschungsge-meinschaft (DFG)
European Research Council
Wilhelm Sander-Stiftung
Bayerische Forschungsstiftung
m4 award of the Bavarian Ministry for Economical Affairs
Go-Bio Initiative
Ernst-Jung-Stiftung
German Cancer Aid
Else Kroner-Fresenius-Stiftung
International Doctoral Program i-Target, Immunotargeting of Cancer - Elite Network of Bavaria
Childhood Cancer Society
Research Council of Norway
Norwegian Health Authority South-East
Norwegian Cancer Society
Research Council of Norway (NFR)
University of Bergen PhD fellowship
Marie Sklodowska-Curie Program Training Network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union
Hector Foundation
Deutsche Forschungsge-meinschaft (DFG)
European Research Council
Wilhelm Sander-Stiftung
Bayerische Forschungsstiftung
m4 award of the Bavarian Ministry for Economical Affairs
Go-Bio Initiative
Ernst-Jung-Stiftung
German Cancer Aid
Else Kroner-Fresenius-Stiftung
International Doctoral Program i-Target, Immunotargeting of Cancer - Elite Network of Bavaria
Childhood Cancer Society